
Annual report 2025
added 01-30-2026
Vallon Pharmaceuticals Net Debt 2011-2026 | VLON
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Vallon Pharmaceuticals
| 2025 | 2024 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.16 M | -4.91 M | - | -48 K | -3.48 M | -613 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -48 K | -8.16 M | -3.44 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.24 | -0.12 % | $ 6.83 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 229.25 | 0.44 % | $ 5 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
AbbVie
ABBV
|
59.5 B | $ 208.84 | -2.86 % | $ 369 B | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.52 | 0.28 % | $ 1.05 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-60.8 M | $ 3.33 | -2.06 % | $ 99 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
65 M | $ 14.81 | 2.63 % | $ 2.25 B | ||
|
Altimmune
ALT
|
-9.22 M | $ 3.34 | 7.05 % | $ 294 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.18 | 1.97 % | $ 27.2 B | ||
|
Amgen
AMGN
|
41 B | $ 347.94 | -1.51 % | $ 187 B | ||
|
ANI Pharmaceuticals
ANIP
|
166 M | $ 74.21 | -2.3 % | $ 1.43 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 8.03 | 2.29 % | $ 220 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
-26.8 M | $ 15.61 | 0.9 % | $ 2.1 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.41 | 2.17 % | $ 375 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.68 | 1.52 % | $ 16.8 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.14 | -2.59 % | $ 683 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Atea Pharmaceuticals
AVIR
|
-63.1 M | $ 5.76 | 1.95 % | $ 469 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
211 M | $ 9.02 | -3.84 % | $ 1.86 B | ||
|
Axcella Health
AXLA
|
1.5 M | - | -16.42 % | $ 249 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 412.81 | -2.54 % | $ 31.3 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 318.85 | -3.01 % | $ 41.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |